Guardant Health earnings date
Guardant Health (5GH) Q3 2026 Earnings Report
DE:5GH Q3 2026 EPS Results
- Actual EPS
- -EUR 0.84
- Consensus EPS
- -EUR 0.68
- Beat/Miss
- Missed by -EUR 0.16
- One Year Ago EPS
- -EUR 0.67
DE:5GH Q3 2026 Revenue Results
- Actual Revenue
- EUR 326.30M
- Expected Revenue
- EUR 317.03M
- Beat/Miss
- Beat by +EUR 9.27M
- YoY Revenue Growth
- +36.12%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Guardant Health's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, supported by 36% companywide revenue growth, 180% Shield revenue growth, 58% oncology volume growth, raised full-year revenue guidance, major FDA and reimbursement milestones, and improving gross margin, EBITDA loss, and cash burn. The primary challenges were continued operating expenses and reinvestment, higher full-year free cash flow burn guidance due partly to a CMS payment timing delay, and ongoing reimbursement, contracting, and regulatory work for several products.
For full year 2026, Guardant raised revenue guidance to a range of $1.36 billion to $1.37 billion, representing year-over-year growth of approximately 38% to 40% versus the prior outlook of 36% to 38%; Oncology revenue growth is expected to be approximately 30% with volume growth of more than 50%, biopharma and data growth remains unchanged at low double-digit growth, and screening revenue guidance is $233 million to $238 million with 285,000 to 290,000 field tests. The company expects full year non-GAAP gross margin of 65%, 2026 non-GAAP operating expenses of approximately $1.105 billion to $1.125 billion, representing growth of 22% to 24% compared with 2025, and full year free cash flow burn of $205 million to $220 million versus the prior outlook of $195 million to $205 million, including $10 million to $15 million in payments shifting to the first half of 2027; excluding screening, the remainder of the business will generate positive free cash flow for the full year 2026, and the company remains confident in achieving company-wide free cash flow breakeven by the end of 2027. The company expects Shield coverage for approximately 100 million people or greater than 80% of the total eligible U.S. screening population in 2027, Shield cost per test of $200 by the end of 2028, screening as a stand-alone business to be cash flow breakeven by the end of 2028, Guardant360 Liquid CDx ADLT designation in the first half of 2027, Reveal Ultra clinical launch by the year-end, and Guardant360 Tissue FDA approval hopefully sometime next year following a process that usually takes about 12 months.
- Strong Companywide Revenue GrowthThird quarter revenue grew 36% year over year to $361 million, up from $265 million a year ago, with contributions from oncology, biopharma and data, and screening.
- Oncology Revenue and Volume ExpansionOncology revenue increased 25% year over year to $231 million, while oncology test volumes rose 58% to 117,000 tests from 74,000 in the prior-year period. Management attributed the growth to strength across therapy selection and monitoring products, increasing clinical utility from Smart Apps, and greater interconnectivity across late-stage and early-stage disease.
- Broad Growth Across Oncology ProductsGuardant360 Liquid volume grew nearly 30% in the third quarter and was on track for roughly 30% volume growth for the full year. Guardant360 Tissue delivered record sequential growth and remained the second fastest-growing oncology product, while Reveal volume growth was well in excess of 100% and more than doubled year over year.
- FDA Approval for ESR1 MonitoringGuardant received landmark FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH. The test identifies emerging ESR1 mutations in advanced breast cancer before progression is visible on imaging and can help inform an earlier treatment change. Guardant360 CDx became the only FDA-approved companion diagnostic for ESR1-targeted therapies.
- Guardant360 CDx Reimbursement MilestonesThe PLA code for Guardant360 Liquid CDx was finalized in October, providing a dedicated billing code, and the ADLT application was submitted. Guardant remains on track for ADLT designation in the first half of 2027.
- Guardant360 Tissue PMA SubmissionGuardant submitted its PMA application for Guardant360 Tissue to the FDA. The assay combines comprehensive DNA profiling, transcriptome RNA, and genome-wide methylation analysis in a single test and has one of the lowest sample input requirements among comprehensive genomic profiling tissue tests.
- Scale of Guardant's Data PlatformGuardant has run more than 1.5 million patient tests and generated more than 900,000 epigenetic profiles across more than 100 tumor types. This data supports the InfinityAI learning engine, which combines genomic, epigenomic, claims, longitudinal EMR, and clinical data to generate insights, products, and real-world evidence.
- Expansion of Smart App CapabilitiesGuardant planned to launch the fourth wave of Smart Apps on Guardant360 Liquid, including 11 releases and the first Smart Apps using methylation signatures to predict therapy benefit. New applications include a SERD benefit predictor and two advanced lung cancer apps designed to help select immunotherapy, including one that provides PD-L1 information directly from a blood draw.
- Reveal Melanoma EvidenceIn the COSMOS-MEL01 prospective multicenter melanoma study, Guardant Reveal detected 81% of distant recurrences while demonstrating 100% specificity. Circulating tumor DNA was detected approximately 3 months before recurrence was identified clinically, and Guardant expects to submit Reveal melanoma to MolDX in the coming months.
- Reveal Ultra ProgressReveal Ultra demonstrated a limit of detection at one part per million or below across major tumor types. More than 4,000 samples have been processed across multiple studies, the product has been launched to biopharma partners, and Guardant remains confident in a clinical customer launch before year-end.
- Biopharma Companion Diagnostic ApprovalsThe biopharma and data business generated $59 million of third-quarter revenue, up 8% from $55 million a year ago, and delivered record test volumes. Guardant received three new companion diagnostic approvals during the quarter, bringing its cumulative total to 31 globally.
- Exceptional Shield Revenue GrowthScreening revenue increased 180% year over year to $68 million from $24 million. Shield volume increased 246% to 83,000 tests from 24,000 in the prior-year period, reflecting commercial infrastructure scale-up and improved field organization productivity.
- Shield Commercial MomentumManagement cited the Quest collaboration, national healthcare provider and direct-to-consumer campaigns, and American Cancer Society guideline inclusion as contributors to Shield adoption. Management also said field representative productivity was higher than expected and that national direct-to-consumer campaigns were generating a positive impact.
- Expanded Shield CoverageUnitedHealthcare coverage became effective in August, with favorable policy updates also received from Carelon and EviCore. Additional favorable coverage decisions came from EmblemHealth, Blue Cross Blue Shield of Kansas City, and Exelis. These policies added approximately 30 million covered lives in the quarter.
- Broad Expected Shield Access by 2027Guardant estimates that approximately 100 million people, or more than 80% of the total eligible U.S. screening population, will be covered for the Shield blood test as the company enters 2027. Pennsylvania also enacted legislation expanding access to guideline-recommended blood-based colorectal cancer screening without patient cost sharing.
- Shield Multi-Cancer Detection InitiativeShield's workflow allows physicians to screen for colorectal cancer and, if patients opt in, receive multi-cancer detection results. Management reported increasing physician and patient participation, with each result expanding the real-world data set and supporting the regulatory and reimbursement strategy for Shield MCD.
- Shield ASP and Cost Per Test ImprovementShield average selling price was above $800 in the third quarter, supported by Medicare fee-for-service reimbursement, Medicare Advantage progress, and improved commercial reimbursement. The lower-cost, high-throughput workflow reduced Shield cost per test from $410 in the second quarter to $330 in the third quarter, surpassing the year-end target of $350 one quarter ahead of schedule.
- Planned Further Shield Cost ReductionGuardant expects additional cost reductions from scaling efficiencies and automation at its new Palo Alto laboratory, scheduled to go live in 2027. The company is targeting Shield cost per test of $200 by the end of 2028.
- Improved Gross Margin and Cash UseThird-quarter non-GAAP gross margin improved to 67% from 66% a year ago, while non-GAAP gross profit increased by $66 million. Adjusted EBITDA loss improved to $37 million from $46 million, and free cash flow burn improved to $37 million from $46 million in the prior-year period. Quarter-end cash and investments were $1.1 billion.
- Raised Full-Year Revenue GuidanceGuardant raised 2026 revenue guidance to $1.36 billion to $1.37 billion, representing approximately 38% to 40% year-over-year growth versus the prior outlook of 36% to 38%. Oncology revenue growth is still expected to be approximately 30%, with oncology volume growth now expected to exceed 50%.
- Raised Screening GuidanceFull-year screening revenue guidance was raised to $233 million to $238 million, with expected field tests of 285,000 to 290,000. Management cited continued volume momentum, commercial execution, ACS guideline inclusion, and progress with commercial payer coverage.
- Path to Cash Flow BreakevenManagement stated that, excluding screening, the remainder of the business is expected to generate positive free cash flow for full-year 2026 with improved cash generation year over year. Guardant remains confident in achieving companywide free cash flow breakeven by the end of 2027 and screening as a standalone business reaching cash flow breakeven by the end of 2028.
DE:5GH Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.68- | -0.9 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.68-0.84 | -0.67 | -25.68% (-0.17) | |
| Jul 30, 2026 | 2026 (Q2) | -0.69-0.81 | -0.72 | -12.50% (-0.09) | |
| May 07, 2026 | 2026 (Q1) | -0.73-0.77 | -0.7 | -10.39% (-0.07) | |
| Feb 19, 2026 | 2025 (Q4) | -0.69-0.90 | -0.81 | -11.11% (-0.09) | |
| Oct 29, 2025 | 2025 (Q3) | -0.71-0.67 | -0.8 | 15.91% (+0.13) | |
| Jul 30, 2025 | 2025 (Q2) | -0.67-0.72 | -0.76 | 4.76% (+0.04) | |
| Apr 30, 2025 | 2025 (Q1) | -0.71-0.70 | -0.85 | 18.09% (+0.15) | |
| Feb 20, 2025 | 2024 (Q4) | -0.70-0.81 | -1.43 | 43.04% (+0.61) | |
| Nov 06, 2024 | 2024 (Q3) | -0.66-0.80 | -0.66 | -20.55% (-0.14) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


